Liangbo Shen, MD, discussed unmet needs in geographic atrophy and how implants could ease treatment burden.
Commentary|Articles|October 19, 2026
Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA
Author(s)Jordi Mones, MD, PhD, Kassi Filkins
Jordi Monés, MD, PhD, explains why RP and Stargardt data support testing son-vec to restore vision in advanced GA.
Advertisement
Advertisement
The 2 complement inhibitors approved by the US Food and Drug Administration (FDA) for
Related to this article
Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.
Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual effects.
Kenneth C. Fan, MD, MBA, shared 4-year REMAIN data showing durable vision gains with MCO-010 in retinitis pigmentosa.
Liangbo Linus Shen, MD, shared phase 2 data showing kamuvudine K8 reduced geographic atrophy growth by 54%.
OT Roundup covers the optogenetics Nobel Prize, remigromig in DME with Veeral Sheth, MD, Stargardt disease and a total human eye transplant.
FDA accepts vamikibart BLA for UME as data show sustained gains at 1 year; decision July 2027.
Anti-VEGF for ROP is not associated with systemic and neurodevelopmental outcomes.
Advertisement
Advertisement